BOSTON, MA, Ascidian Therapeutics, a biotechnology company, announced $40 million in Series A extension funding committed by Apple Tree Partners.
Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced $40 million in Series A extension funding committed by Apple Tree Partners (ATP). This financing follows ATP's initial $50 million Series A investment in Ascidian announced in October 2022.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
